Hyperoxaluria - Pipeline Review, H1 2016 Summary Global Markets Direct's, 'Hyperoxaluria - Pipeline Review, H1 2016', provides an overview of the Hyperoxaluria pipeline landscape. The report provides comprehensive information on the therapeutics under development for Hyperoxaluria, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Hyperoxaluria and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape of Hyperoxaluria - The report reviews pipeline therapeutics for Hyperoxaluria by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved Hyperoxaluria therapeutics and enlists all their major and minor projects - The report assesses Hyperoxaluria therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news related to pipeline therapeutics for Hyperoxaluria Reasons To Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Hyperoxaluria - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Hyperoxaluria pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2 List of Tables 4 List of Figures 5 Introduction 6 Global Markets Direct Report Coverage 6 Hyperoxaluria Overview 7 Therapeutics Development 8 Pipeline Products for Hyperoxaluria - Overview 8 Hyperoxaluria - Therapeutics under Development by Companies 9 Hyperoxaluria - Pipeline Products Glance 10 Clinical Stage Products 10 Early Stage Products 11 Hyperoxaluria - Products under Development by Companies 12 Hyperoxaluria - Companies Involved in Therapeutics Development 13 Allena Pharmaceuticals, Inc. 13 Alnylam Pharmaceuticals, Inc. 14 Dicerna Pharmaceuticals, Inc. 15 Digna Biotech, S.L. 16 OxThera AB 17 Hyperoxaluria - Therapeutics Assessment 18 Assessment by Monotherapy Products 18 Assessment by Target 19 Assessment by Mechanism of Action 21 Assessment by Route of Administration 23 Assessment by Molecule Type 25 Drug Profiles 27 ALLN-177 - Drug Profile 27 Product Description 27 Mechanism of Action 27 R&D Progress 27 ALLN-230 - Drug Profile 29 Product Description 29 Mechanism of Action 29 R&D Progress 29 ALN-GO1 - Drug Profile 30 Product Description 30 Mechanism of Action 30 R&D Progress 30 DB-027 - Drug Profile 32 Product Description 32 Mechanism of Action 32 R&D Progress 32 DCR-PH - Drug Profile 33 Product Description 33 Mechanism of Action 33 R&D Progress 33 DCRPH-1 - Drug Profile 34 Product Description 34 Mechanism of Action 34 R&D Progress 34 Oxabact - Drug Profile 36 Product Description 36 Mechanism of Action 36 R&D Progress 36 Hyperoxaluria - Recent Pipeline Updates 38 Hyperoxaluria - Dormant Projects 42 Hyperoxaluria - Discontinued Products 43 Hyperoxaluria - Product Development Milestones 44 Featured News & Press Releases 44 May 13, 2016: Dicerna Announces Dosing of First Patient in Phase 1 Clinical Trial of DCR-PH1 in Patients with Primary Hyperoxaluria Type 1 44 May 05, 2016: FDA Grants Orphan Drug Designation to Allena's Investigational Therapy for the Treatment of Pediatric Hyperoxaluria 45 Feb 10, 2016: Allena Pharmaceuticals Initiates Patient Treatment in Third Phase 2 Trial of ALLN-177 for Secondary Hyperoxaluria 45 Dec 21, 2015: Dicerna Begins Dosing in First Clinical Trial of Therapy for Primary Hyperoxaluria Type 1 in Healthy Volunteers 46 Nov 12, 2015: Allena Pharmaceuticals Announces Presentation of Successful Phase 2 Data from ALLN-177 Program at American Society of Nephrology Kidney Week 48 Nov 04, 2015: Allena Pharmaceuticals to Present Phase 2 Data on ALLN-177 Program at ASN Kidney Week 2015 49 Sep 02, 2015: Dicerna Pharmaceuticals Submits Investigational New Drug Application for DCR-PH1, an Investigational Therapy for Primary Hyperoxaluria Type 1 (PH1) 49 Aug 06, 2015: EMA Grants Orphan Drug Designation to DCR-PH1, Dicerna's Investigational Therapy for the Treatment of Primary Hyperoxaluria Type 1 50 Aug 04, 2015: Allena Pharmaceuticals Initiates Phase 2b Trial of ALLN-177 for Secondary Hyperoxaluria 50 Apr 23, 2015: FDA Grants Orphan Drug Designation for DCR-PH1, Dicerna's Investigational Therapy for the Treatment of Primary Hyperoxaluria Type 1 (PH1) 51 Appendix 52 Methodology 52 Coverage 52 Secondary Research 52 Primary Research 52 Expert Panel Validation 52 Contact Us 52 Disclaimer 53
List of Tables
Number of Products under Development for Hyperoxaluria, H1 2016 8 Number of Products under Development by Companies, H1 2016 9 Comparative Analysis by Clinical Stage Development, H1 2016 10 Comparative Analysis by Early Stage Development, H1 2016 11 Products under Development by Companies, H1 2016 12 Hyperoxaluria - Pipeline by Allena Pharmaceuticals, Inc., H1 2016 13 Hyperoxaluria - Pipeline by Alnylam Pharmaceuticals, Inc., H1 2016 14 Hyperoxaluria - Pipeline by Dicerna Pharmaceuticals, Inc., H1 2016 15 Hyperoxaluria - Pipeline by Digna Biotech, S.L., H1 2016 16 Hyperoxaluria - Pipeline by OxThera AB, H1 2016 17 Assessment by Monotherapy Products, H1 2016 18 Number of Products by Stage and Target, H1 2016 20 Number of Products by Stage and Mechanism of Action, H1 2016 22 Number of Products by Stage and Route of Administration, H1 2016 24 Number of Products by Stage and Molecule Type, H1 2016 26 Hyperoxaluria Therapeutics - Recent Pipeline Updates, H1 2016 38 Hyperoxaluria - Dormant Projects, H1 2016 42 Hyperoxaluria - Discontinued Products, H1 2016 43
List of Figures
Number of Products under Development for Hyperoxaluria, H1 2016 8 Number of Products under Development by Companies, H1 2016 9 Comparative Analysis by Clinical Stage Development, H1 2016 10 Comparative Analysis by Early Stage Products, H1 2016 11 Assessment by Monotherapy Products, H1 2016 18 Number of Products by Targets, H1 2016 19 Number of Products by Stage and Targets, H1 2016 19 Number of Products by Mechanism of Actions, H1 2016 21 Number of Products by Stage and Mechanism of Actions, H1 2016 21 Number of Products by Routes of Administration, H1 2016 23 Number of Products by Stage and Routes of Administration, H1 2016 23 Number of Products by Molecule Types, H1 2016 25 Number of Products by Stage and Molecule Types, H1 2016 25
Global automotive ECU market is projected to be valued at USD 45.98 billion by 2020, as per a new research report by Radiant Insights, Inc. Rising use in infotainment systems coupled with high deployment in electric vehicles applications is expectedRead More...
Global activated carbon market size is likely to be valued at USD 5.3 billion by 2020; as per a new research report by Radiant Insights, Inc. Increase in commercial & residential waste water treatment demand owing to escalation in water prices is antRead More...
Global gold nanoparticles market size is expected to reach 4.99 billion by 2020, witnessing gains at a CAGR of 24.7%. Positive outlook towards the increasing applications of nanotechnology in medical and dentistry such as drug delivery systems, nanomRead More...
Global Bio polyethylene terephthalate (PET) market size is likely to be valued at USD 12.6 billion by 2020; as per a new research report by Radiant Insights, Inc. Growing preference of biopolymers in numerous applications coupled with favorable goverRead More...
Global fumaric acid market size is anticipated to be valued at USD 764.8 million by 2020, as per a new research report by Radiant Insights, Inc. Growing processed food demand coupled with RTD (ready-to-drink) beverages consumption is expected to drivRead More...
Toll Free: 1-888-928-9744
Email: [email protected]
Speak to the report author to design an exclusive study to serve your research needs.
A testimonial for service excellence represented in the form of BBB "A" Accreditation.
Your personal and confidential information is safe and secure.